PAUL STEVEN M — SEC insider filings

SEC reporting owner CIK 1237564. 25 insider filings on record with FilingPulse; latest filed 2026-10-22.

Transaction summary — filings shown

Covers all 25 filings on record, filed 2020-12-22 to 2026-10-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
ALNYLAM PHARMACEUTICALS, INC. (ALNY)Director3—11 legs · 30,000 sh · $4,660,3715
Rapport Therapeutics, Inc. (RAPP)Director43 legs · 77,380 sh · $2,001,389—2
Karuna Therapeutics, Inc. (KRTX)Director82 legs · 2,364 sh · $250,264—38
Sage Therapeutics, Inc. (SAGE)Director8——8
Seaport Therapeutics, Inc. (SPTX)Director1——4
Voyager Therapeutics, Inc. (VYGR)Director1——1

Insider filings — PAUL STEVEN M

FiledFormIssuerReported transactionsSource
2026-10-224Rapport Therapeutics, Inc. (RAPP)Purchase (P): 35,714 @ $27.28EDGAR
2026-06-104Rapport Therapeutics, Inc. (RAPP)Grant/award (A): 15,200 (derivative) @ $0EDGAR
2026-05-044Seaport Therapeutics, Inc. (SPTX)Conversion (C): 67,031 · Grant/award (A): 12,258 (derivative) @ $0 · Grant/award (A): 991,192 (derivative) @ $0 · Conversion (C): 210,526 (derivative) @ $0EDGAR
2025-09-154Rapport Therapeutics, Inc. (RAPP)Purchase (P): 28,284 @ $24.50 · Purchase (P): 13,382 @ $24.97EDGAR
2025-06-184Rapport Therapeutics, Inc. (RAPP)Grant/award (A): 21,850 (derivative) @ $0EDGAR
2024-03-184Karuna Therapeutics, Inc. (KRTX)Disposition to issuer (D): 2,046 @ $330 · Disposition to issuer (D): 8,550 @ $330 · Disposition to issuer (D): 30,304 @ $330 · Disposition to issuer (D): 10,000 @ $330 · Disposition to issuer (D): 33,882 @ $330 · Disposition to issuer (D): 30,304 @ $330 · +12 moreEDGAR
2024-03-044Karuna Therapeutics, Inc. (KRTX)Other (J): 47,378 @ $315.18 · Gift (G): 30,304 @ $0 · Gift (G): 30,304 @ $0 · Gift (G): 30,304 @ $0 · Gift (G): 30,304 @ $0 · Gift (G): 30,304 @ $0 · +1 moreEDGAR
2024-02-264Karuna Therapeutics, Inc. (KRTX)Option exercise (M): 27,510 @ $7.27 · Option exercise (M): 4,008 @ $99.72 · Option exercise (M): 27,510 (derivative) @ $0 · Option exercise (M): 4,008 (derivative) @ $0EDGAR
2024-02-124Karuna Therapeutics, Inc. (KRTX)Tax withholding (F): 804 @ $317.14EDGAR
2024-01-044Sage Therapeutics, Inc. (SAGE)Grant/award (A): 3,971 (derivative) @ $0EDGAR
2023-06-164Sage Therapeutics, Inc. (SAGE)Grant/award (A): 10,000 (derivative) @ $0EDGAR
2023-02-134Karuna Therapeutics, Inc. (KRTX)Gift (G): 106,485 @ $0 · Gift (G): 106,485 @ $0 · Gift (G): 106,485 @ $0 · Gift (G): 106,485 @ $0 · Grant/award (A): 11,400 @ $0 · Grant/award (A): 22,800 (derivative) @ $0EDGAR
2023-01-054Sage Therapeutics, Inc. (SAGE)Grant/award (A): 2,395 (derivative) @ $0EDGAR
2022-11-304Sage Therapeutics, Inc. (SAGE)Other (J): 5 @ $38.17EDGAR
2022-06-174Sage Therapeutics, Inc. (SAGE)Grant/award (A): 9,947 (derivative) @ $0EDGAR
2022-04-054ALNYLAM PHARMACEUTICALS, INC. (ALNY)Option exercise (M): 15,000 @ $11.33 · Sale (S): 253 @ $166.04 · Sale (S): 4,948 @ $168.95 · Sale (S): 4,872 @ $169.71 · Sale (S): 1,235 @ $171.16 · Sale (S): 1,434 @ $172.10 · +6 moreEDGAR
2022-02-174Karuna Therapeutics, Inc. (KRTX)Grant/award (A): 146,900 (derivative) @ $0EDGAR
2022-01-054Sage Therapeutics, Inc. (SAGE)Grant/award (A): 1,638 (derivative) @ $0EDGAR
2021-11-124Sage Therapeutics, Inc. (SAGE)Other (J): 1 @ $43.36EDGAR
2021-08-184Karuna Therapeutics, Inc. (KRTX)Purchase (P): 1,183 @ $105.63 · Purchase (P): 1,181 @ $106.10EDGAR
2021-07-194ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 4,032 (derivative) @ $0EDGAR
2021-06-114Sage Therapeutics, Inc. (SAGE)Grant/award (A): 10,000 (derivative) @ $0EDGAR
2021-06-044Voyager Therapeutics, Inc. (VYGR)Grant/award (A): 15,000 (derivative) @ $0EDGAR
2021-02-244Karuna Therapeutics, Inc. (KRTX)Grant/award (A): 161,850 (derivative) @ $0EDGAR
2020-12-224ALNYLAM PHARMACEUTICALS, INC. (ALNY)Option exercise (M): 15,000 @ $9.30 · Sale (S): 15,000 @ $140 · Option exercise (M): 15,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-12-17 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1237564 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs